Research Article

Effects of Guchang Capsule on Dextran Sulphate Sodium-Induced Experimental Ulcerative Colitis in Mice

Baoshan Liu,1 Tong Liu,2 Xiaohong Wang,1 Xin Zheng,2 Hong Wang,1 and Lin Ma1

1Department of Traditional Chinese Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
2Tianjin Zhongxin Pharmaceutical Group Corporation LTD., Tianjin 300457, China

Correspondence should be addressed to Baoshan Liu; baoshanliu621@163.com

Received 1 February 2016; Revised 1 May 2016; Accepted 5 May 2016

Academic Editor: Ho Lin

Copyright © 2016 Baoshan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Guchang capsule (GC) is a Chinese materia medica standardized product extracted from 15 Chinese traditional medical herbs and it has been clinically used in the treatment of intestinal disease. In this study, in order to extend the research of GC in intestinal disease, we were aiming to evaluate potential effects of GC on dextran sulphate sodium- (DSS-) induced murine experimental colitis and to elucidate the underlying mechanisms. GC treatment attenuated DSS-induced body weight loss and reduced the mortality. Moreover, GC treatment prevented DSS-induced colonic pathological damage; meanwhile it inhibited proinflammatory cytokines production in colon tissues.

In vitro, GC significantly reduced LPS-induced proinflammatory cytokines production via inhibiting the activation of NF-κB in macrophage cells, and the expressions of several long noncoding RNAs (lncRNAs) which were reported in regulating NF-κB signaling pathway were obviously affected by adding GC into culture medium. In conclusion, our data suggested that administration of GC exhibits therapeutic effects on DSS-induced colitis partially through regulating the expression of NF-κB related lncRNAs in infiltrating immune cells.

1. Introduction

Ulcerative colitis (UC) and Crohn’s disease (CD), which are considered inflammatory bowel diseases (IBDs), are chronic gastrointestinal disorders characterized by inflammation in the intestine and colon, as well as mucosal tissue damage [1]. Although many studies suggest that genetic and environmental factors, infection, and immune system disorders are involved in the development of UC, its cause and underlying mechanisms remain unclear [2]. Several animal models of experimental colitis have been developed to help investigate the molecular and cellular mechanisms of the disease. Among these, the dextran sodium sulfate- (DSS-) induced experimental colitis model is one of the best studied. It is initiated by DSS-induced damage to the intestinal epithelial cells but is dependent on the presence of both commensal microflora [3, 4]. Similar to human IBD, DSS-induced colitis is limited to the colonic mucosa and is characterized by diarrhea, bloody feces, weight loss, colonic ulceration, and a histopathological picture of inflammation, consisting mainly of infiltrating macrophages and granulocytes [3, 4].

NF-κB has represented a paradigm for signal transduction and gene regulation implicated in numerous diseases including malignancies and chronic inflammatory disorders [5, 6]. NF-κB is normally sequestered in the cytoplasm by a family of inhibitory proteins known as inhibitors of NF-κB (IκB). Upon activation, IκB is phosphorylated by the IκB kinase (IKK) complex, and the phosphorylation of IκB results in its degradation [7]. Subsequently, NF-κB is translocated to the nucleus and initiates downstream target genes transcription related to inflammation and immunity [6]. It has been reported that NF-κB plays a critical role at IBD onset in Crohn’s disease (CD) and UC patients as well as experimental colitis models [8, 9].

Recently, pathogenic mechanism of UC is considered to be dysregulation of the intestinal immune response to intestinal environmental antigens, such as gut microbiota [10, 11]. Lipopolysaccharide (LPS), major constituent of outer membranes of Gram-negative bacteria, is a pivotal risk factor and prominent stimulus for inflammatory mediators releasing [12]. LPS would trigger the innate immune systems by activating Toll-like receptors (TLRs) superfamily in innate
immune cells such as dendritic cells and macrophages [13, 14]. Among TLRs, TLR4 is a major LPS receptor and mediates the most of inflammation responses to LPS by activating NF-κB protein, via myeloid differentiation factor 88- (MyD88-) dependent and MyD88-independent pathway [13–15]. Then, the activated NF-κB induces the productions of proinflammatory cytokines such as tumor necrosis factor-α (TNFα), interleukin-1β (IL-1β), and IL-6 [14–16], resulting in severe intestinal injury and formation of UC. Alteration in cytokines production by macrophages is one major component of the pathology of UC. Therefore, strategies for targeting inflammatory macrophages and focusing on downregulating the TLR4/NF-κB signaling pathways inflammatory responses would provide potential therapeutic effects for UC.

Recent advances in large-scale RNA sequencing (RNA-seq) have led to the identification of novel RNA species encoded in the genome, many of which are long noncoding RNAs (lncRNAs) [17, 18]. lncRNAs are arbitrarily defined as having ≥200 nt, which discriminates them from small noncoding RNAs. lncRNAs have emerged as important regulators of gene expression, with an accumulating body of evidence linking lncRNAs to a plethora of human pathways, including inflammatory diseases [19]. Meanwhile, the role of lncRNAs in intestinal diseases remains poorly understood.

Irritable bowel syndrome (IBS) is characterized by abdominal pain or discomfort associated with altered bowel function, such as constipation or diarrhea, without significant structural changes or inflammation [20]. IBD is characterized by abundant inflammation in the bowel which can result in symptoms such as abdominal pain, cramping, diarrhea, and bloody stools. Approximately 60–80% of patients with IBD suffer from irritable IBS-like symptoms such as increased abdominal pain, bloating, distention, and stool alteration [21, 22].

Traditional Chinese medicine has been widely used in many kinds of diseases and has shown excellent curative effect [23, 24]. Guchang capsule (GC) is a Chinese materia medica standardized product extracted from 15 Chinese traditional medical herbs and is widely used for treatment of patients with irritable bowel syndrome (IBS) in clinical setting. However, the function of GC in IBD and the molecular mechanisms still remain unclear. Because of the overlapping symptom of IBS and IBD, we hypothesized if GC could have beneficial effect on IBD. In this paper, we described the effect of GC in DSS-induced experimental colitis which extended the research of GC in intestinal disease and explored the underlying mechanisms which may be associated with the production of inflammation related lncRNAs.

2. Materials and Methods

2.1. Vegetal Materia and Reagents. Guchang capsule (GC) consists of Halloysite, Codonopsis, Phellodendron amurense, Myrobalan, Nutmeg, Cortex Magnoliae officinalis, Fructus Evodiae, Qu Jinan, Cinnamon, Rhizoma Zingiberis, Chinese Prickly Ash, Ligusticum wallichii, Concha Ostreeae, Gallnut, and Dark Plum Fruit (Zhongxin Pharmaceutical Corporation, Tianjin, China). We dissolved the drug powder in sterile water at 0.1 g/mL GC for the further study: in vivo, GC were given intragastrically (2 g/kg); in vitro, GC were added into culture medium at a final concentration of 1 mg/mL. LPS (E. coli: Serotype O55:B5) and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a final concentration of 100 ng/mL. Dextran sulfate sodium (DSS, molecular weight 36–50 kDa) was obtained from MP Biomedicals Inc. (Irvine, CA, USA).

2.2. Mice and Cells. Male C57BL/6J mice weighing 20–25 g (aged 8–10 weeks) were used in this study; all mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The animals were fed a standard diet and water was provided ad libitum. The mice were kept at room temperature (controlled at 25°C) with a light-dark cycle of 12 h each day. The experiments were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals approved by the Animal Ethics Committee of the Scientific Investigation Board of Tianjin Medical University. Mouse macrophage cell line RAW264.7 and human monocytic leukemia cell line THP-1 were obtained from American Type Culture Collection (Manassas, VA). The cells were cultured at 37°C under 5% CO2 in DMEM supplemented with 10% FBS (Invitrogen, Life Technologies), 100 U/mL penicillin, and 100 mg/mL streptomycin. Differentiation of THP-1 monocytes to human macrophages was induced by 0.5 mM phorbol 12-myristate 13-acetate (PMA) for 3 h; the differentiated cells were washed three times with PBS, followed by the further experiments.

2.3. Induction and Evaluation of DSS-Induced Colitis. The mice were randomly assigned to control, GC, control + DSS-treated, and GC + DSS-treated groups. Experimental colitis was induced by adding DSS to the drinking water to a final concentration of 4% (w/v) for 6 days; subsequently, mice were sacrificed at day 6 to separate the colons for tissue experiments or switched to regular drinking water until 15 days for survival data monitoring. The animals were given free access to water containing DSS for 6 days. Control animals received water without DSS. GC were given intragastrically once per day for 6 days from the first day, respectively. Mice were examined daily to determine their clinical disease activity index (DAI), which was based on the degree of body weight loss, stool consistency, and fecal blood (ranging from 0 to 12). Briefly, DAI was scored as follows: weight loss (no change = 0; <5% = 1; 6–10% = 2; 11–20% = 3; >20% = 4), stool (normal = 0; soft, well-formed = 1; soft without pellets = 2; diarrhea = 4), and blood (no blood = 0; visible blood in rectum = 1; gross bleeding in rectum = 2; visible blood on fur = 4). For histological analysis, the distal colonic specimens were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with H&E, and pathological scores, ranging from 0 to 6 (combining inflammatory cell infiltration score and tissue damage score), were determined as follows: inflammatory cell infiltration in the lamina propria (occasional inflammatory cells = 0; increased inflammatory cells = 1; confluenf of inflammatory
cells extending to the submucosa = 2; transmural extension = 3) and tissue damage (no mucosal damage = 0; lymphoepithelial lesions = 1; surface mucosal erosion = 2; extensive mucosal damage and extension into deeper structures of the bowel wall = 3).

2.4. ELISA. Distal parts of colonies were homogenized in CellLytic buffer (Sigma-Aldrich, St. Louis, MO) supplemented with complete protease inhibitor mixture (Roche, Indianapolis, IN). Protein concentration was measured by BCA assay (Pierce, Rockford, USA). Cytokine content was determined with complete protease inhibitor mixture (Roche, Indianapolis, IN). Protein concentration was measured by BCA assay.

2.5. RNA Isolation and Quantitative PCR Analysis. The tissue samples were frozen and mechanically dissociated in TRizol reagent (Invitrogen, Carlsbad, CA). Total RNA was extracted with TRizol reagent according to the manufacturer's instructions. A LightCycler (ABI PRISM 7000; Applied Biosciences) and a SYBR RT-PCR kit (Takara Biotechnology, Dalian, China) were used for real time PCR analysis. GAPDH was used as the internal control, and \( \Delta \Delta CT \) method was used to evaluate the relative quantities of each amplified product in the samples. For each qPCR analysis, three technical replicates were performed. Primer sequences used in quantitative PCR were shown in Table 1.

2.6. Western Blot Analysis. The cells were harvested after stimulation and washed three times by ice-cold PBS (MDL biotech, Beijing, China) on ice, and the cells were lysed with RIPA buffer (MDL biotech, Beijing, China) with protease some inhibitor cocktail (Roche, Indianapolis, IN), followed by sonication. After centrifugation for 15 min at 13,000 g, supernatants were collected and the protein concentration of lysates was measured using Bio-Rad quantification assay (Bio-Rad Laboratories, Hercules, CA). Twenty micrograms of protein sample was incubated with loading buffer (Beyotime, Beijing, China) at 95°C for 10 minutes. Proteins were separated using 10% SDS-PAGE and transferred to a PVDF membrane (Millipore, Billerica, USA). The membrane was then blocked with 2.5% nonfat dry milk for 1 h. The antibodies, which include purified and biotinylated rat anti-mouse TNFα, IL-6, and IL-1β, were purchased from eBioscience and BD Biosciences Pharmingen. Quantitative ELISA was performed according to the manufacturer's instructions.

2.7. Assay of Luciferase Reporter Gene Expression. RAW264.7 macrophages were cotransfected with NF-κB luciferase reporter plasmid and pRL-TK-Renilla-luciferase plasmid using jet-PEI transfection reagent (Polyplus, Illkirch, France) as previously reported [25]. 24 hours after transfection, the cells were left untreated or treated with LPS, with 1 mg/mL GC or sterile water coapplied into culture medium for 4 hours. The cells were harvested and washed by ice-cold PBS for three times and luciferase activities were measured with Dual-Luciferase Reporter Assay System (Promega, Madison, USA), according to the manufacturer's instructions. Data are normalized for transfection efficiency by dividing Firefly

### Table 1: List of primers used in the study.

| Number | Gene       | Primer sequence                  | Primer length |
|--------|------------|----------------------------------|---------------|
| 1      | TNFα       | Forward 5'-GCCACCCACGCTCTTCTGCTCT-3' | 20 bp         |
|        |            | Reverse 5'-AGGGTTCGCTGAGGATCAGA-3' | 21 bp         |
| 2      | IL-6       | Forward 5'-ACATCCTAGGATGAGGACATGA-3' | 22 bp         |
|        |            | Reverse 5'-AACGTCACACCAGGAGGTGTT-3' | 22 bp         |
| 3      | IL-1β      | Forward 5'-ACCTTCCAGGATGAGGACATGA-3' | 20 bp         |
|        |            | Reverse 5'-TCTCCACCCCTGTTTTGT-3' | 20 bp         |
| 4      | GAPDH      | Forward 5'-AGATCCAGATGAGCGCTT-3' | 21 bp         |
|        |            | Reverse 5'-GCCCTAAGAACAGGGCTAGG-3' | 20 bp         |
| 5      | IncRNA Letha| Forward 5'-GAAACAGGTGCACGTTCA-3' | 20 bp         |
|        |            | Reverse 5'-ACAGATGTACCTCGCCAAC-3' | 20 bp         |
| 6      | IncRNA-Cox2| Forward 5'-AAAGGAGCTTGCGTTGTA-3' | 20 bp         |
|        |            | Reverse 5'-GAGGATGAGGTCTTTATG-3' | 20 bp         |
| 7      | IncRNA AS-IL1α| Forward 5'-AGCTCCATGAGGCTTTAG-3' | 21 bp         |
|        |            | Reverse 5'-GCCCTAAGAACAGGGCTAGG-3' | 20 bp         |
| 8      | IncRNA NKILA| Forward 5'-GAAACAGGTGCACGTTCA-3' | 21 bp         |
|        |            | Reverse 5'-ACAGATGTACCTCGCCAAC-3' | 20 bp         |
| 9      | IncRNA THRIL| Forward 5'-AACTCTGATCCTACGTTGATCAT-3' | 24 bp     |
|        |            | Reverse 5'-AAAGGAGCTTGCAAGAGTGGCT-3' | 24 bp     |
| 10     | IncRNA-IL7R | Forward 5'-CCAGCTTCATTGCTTCTCAAT-3' | 24 bp     |
|        |            | Reverse 5'-CGTACAAAGTCTTCTAGGCT-3' | 23 bp     |
luciferase activity with that of Renilla luciferase. NF-κB luciferase reporter plasmid and pRL-TK-Renilla-luciferase plasmid were gifts of X. Cao (Second Military Medical University, Shanghai, China).

2.8. Statistical Analysis. All data are presented as mean ± SD of three independent experiments. Statistical significance was determined with the two-tailed Student’s t-test to compare two groups. One-way ANOVA was performed to compare three or more groups. If the ANOVA analysis was significant, the Newman-Keuls test was applied for comparison between each two groups. The survival curves were plotted according to the Kaplan-Meier method and compared using the log-rank test. A p value of less than 0.05 was considered statistically significant.

3. Results

3.1. Effect of GC on Body Weight, DAI, and Survival Rate in DSS-Treated Mice. To determine the potential role of Guchang capsule (GC) in experimental ulcerative colitis, mice were given 4% DSS for 6 days to induce acute colitis. The consumption of food and water was measured throughout the experiment, and there were no significant differences between the groups (data not shown). As shown in Figure 1(a), DSS-treated colitis mice exhibited profound body weight loss, whereas GC administration could significantly attenuate the loss of body weight. The clinical manifestation of the disease, as reflected by disease activity index (DAI), was markedly higher in the DSS-treated group compared with nontreated control group, but the treatment with GC significantly reduced the clinical scores of the DSS-induced colitis in mice (Figure 1(b)). Furthermore, the mortality of DSS-treated mice was improved by about 50% after GC administration (Figure 1(c)).

3.2. Effect of GC on Histology of Colon in DSS-Treated Mice. Histological examination was also performed to validate the clinical data. DSS treatment induced significant histopathological changes in the colons of control mice that were characterized by massive inflammatory infiltrates and disruption of mucosal structures (Figure 2(a)). However, GC treated mice displayed less severe injury compared with control mice after DSS feeding (Figure 2(a)). The histopathological score of GC treated mice was significantly lower than that of control mice after DSS treatment (Figure 2(b)). After DSS-induced injury, the colon weight of GC treated mice was heavier than that of control mice (Figure 2(d)), and GC treated mice had longer colon length compared to control group after DSS feeding.

3.3. GC Administration Decreased Proinflammatory Cytokines Production in DSS-Treated Mice. To evaluate whether the protection from colitis induced by DSS in mice with GC treatment was associated with a reduction in the production of proinflammatory cytokines, after DSS challenge, expression levels of TNFα, IL-1β, and IL-6 in colons of control or GC treated mice were detected using ELISA (Figure 3(a)) and qPCR (Figure 3(b)). Significantly, both the mRNA and protein levels of proinflammatory cytokine were decreased in GC treated group.

3.4. GC Treatment Decreased Proinflammatory Cytokines Production in LPS Stimulated RAW264.7 Cells. During intestinal mucosa damage, LPS secreted by the intestinal flora will stimulate infiltration of macrophages to activate the production of inflammatory factors, so we examined the effect of GC on LPS stimulated proinflammatory cytokines production in RAW264.7 cells. The same as the above results, the anti-inflammatory activity of GC was also confirmed in LPS stimulated RAW264.7 cells in vitro. Both the mRNA and protein levels of proinflammatory cytokines were decreased in GC treated group compared with control group after LPS stimulation (Figures 4(a) and 4(b)).

3.5. GC Suppressed NF-κB Activation after LPS Stimulation in RAW264.7 Cells. Production of proinflammatory cytokines upon LPS depends mainly on the NF-κB activation, so we hypothesized if GC would affect NF-κB activation. To determine the function of GC on NF-κB activation, first we transfected NF-κB luciferase reporter plasmid into RAW264.7 cells; 24 hours later we stimulated cells with LPS together with GC or PBS treatment for 4 hours and measured luciferase activity. LPS-induced NF-κB activation was greatly decreased by GC treatment compared with control group (Figure 5(a)). Western blotting showed that LPS-induced phosphorylation of NF-κB/p65 and IKKβ and IkBα phosphorylation were all suppressed by GC treatment (Figure 5(b)).

3.6. GC Regulated NF-κB Related IncRNAs Expression. In recent years, lots of long noncoding RNAs (lncRNAs) have been identified in the mammalian genomes, many of which have been implicated in a range of developmental processes and diseases [18, 26–28]. Though most of IncRNAs have been primarily studied in the context of genomic imprinting, developmental process, and cancer, IncRNAs are now emerging as important regulators of both innate and adaptive immune responses [29]. We hypothesized that GC could regulate lncRNAs expression in DSS-induced colitis; then we examined the expression of lncRNAs which were reported in regulating activation of NF-κB pathway. Interestingly, lncRNA Lethe, reported as a negative regulator of NF-κB, was significantly upregulated in GC group after LPS stimulation (Figure 6(a)) or DSS treatment (Figure 6(b)), but lncRNA-Cox2 and lncRNA AS-IL1α expressions were not affected (Figures 6(a) and 6(b)). We also examined the effect of GC on expression of lncRNAs which were reported in human THP-1-derived macrophages after LPS stimulation; we found that expressions of the negative regulatory lncRNA NKILA and lncRNA-IL7R were both upregulated, and the expression of lncRNA THRIL which was reported to downregulate TNFα production was suppressed (Figure 6(c)). These results indicated GC could regulate multiple NF-κB related lncRNAs expressions in murine and human macrophage.
4. Discussion

Guchang capsule has been widely used for treatment of patients with IBS in clinical setting in China; because of the overlapping symptom between IBS and IBD, we wonder if GC could affect IBD progressing and we investigated the effect of GC in murine experimental colitis and revealed the potential molecular mechanisms in current study. To the best of our knowledge, this study is the first to systematically demonstrate the function of GC in DSS-induced murine experimental colitis and reveal the special effect of GC on regulating inflammation associated lncRNA expression. Our results suggested that GC treatment could attenuate DSS-induced injury and suppressed proinflammatory cytokines production in DSS-treated mice or LPS stimulated RAW264.7 cells. Furthermore, we found that GC treatment would inhibit the activation of NF-κB and GC had different regulating effect on several kinds of NF-κB/inflammation associated lncRNA.

Ulcerative colitis (UC) is one of the two major forms of inflammatory bowel diseases (IBDs), which are chronic, relapsing, idiopathic, and inflammatory conditions that are
immunologically mediated. Diarrhea, abdominal pain, and bloody mucopurulent stool are the main clinical symptoms for UC [1, 2]. Currently, there are various evolving therapeutic options for UC. Immunosuppressive drugs such as TNF antibody [30], azathioprine (AZA), and methotrexate (MTX) [31] have been adopted to control the symptoms. However, these immunosuppressants have their limitations in efficacy and safety [32, 33]. Therefore, novel strategies with high efficacy and safety are urgently required.

Establishment of UC by oral administration of DSS in the mouse is a widely used model for studies on this disease because this model resembles human UC and the resulting

Figure 2: Effect of GC on histology of colon in DSS-treated mice. (a) Hematoxylin and eosin- (H&E-) stained sections of colons (original magnification ×100); (b) histopathological score; (c) colon weight; (d) colon length. Colitis was induced by administration of 4% DSS for 6 days. GC were given intragastrically once per day for 6 days from the first day, respectively. The mice were sacrificed at day 6 and colons were excised for indicated experiments. The data are representative of three independent experiments (n = 5 per group, mean ± SD). *p < 0.05 versus control + DSS group, **p < 0.01 versus control + DSS group, and #p < 0.05 versus control group.
Figure 3: GC administration decreased proinflammatory cytokines production in DSS-treated mice. (a) ELISA analysis of secreted proinflammatory cytokines; (b) qPCR analysis of mRNA level of proinflammatory cytokines. Colitis was induced by administration of 4% DSS for 6 days. GC were given intragastrically once per day for 6 days from the first day, respectively. The mice were sacrificed at day 6. The protein level (a) or mRNA level (b) of TNF-\(\alpha\), IL-6, and IL-1\(\beta\) in distal part of colons was analyzed. The data are representative of three independent experiments (\(n=5\) per group, mean \(\pm\) SD). *\(p<0.05\) versus control + DSS group, **\(p<0.01\) versus control + DSS group, and #\(p<0.05\) versus control group.

Acute ulcerative colitis induced by DSS showed intestinal bacterial infection and was characterized by massive infiltration of proinflammatory cells, such as macrophages, neutrophils, and CD4+ T cells, within the colonic walls, which destroy epithelium and shorten the colon length [34]. These infiltrated inflammatory cells are major producers of inflammatory mediators, such as TNF-\(\alpha\), IL-6, and IL-1\(\beta\), which contribute to pathogenesis [4]. Activation of NF-\(\kappa\)B is thought of as a strong inducer of these proinflammatory cytokine expressions [35, 36] and has been proposed as a major culprit and therapeutic target for IBD. Recent studies showed that many traditional Chinese medicines showed protective effect on DSS-induced colitis in mice. Song et al. reported that black tea extract could prevent LPS-induced NF-\(\kappa\)B signaling and attenuates DSS-induced experimental colitis [37]; Li et al. showed that Calculus Bovis Sativus (CBS) had protective effect on DSS-induced colitis and CBS significantly downregulated the mRNA expression of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 in the colon tissue [38]. Dave et al. found that mulberry fruit prevents LPS-induced NF-\(\kappa\)B/pERK/MAPK signals in macrophages and suppresses acute colitis and colorectal tumorigenesis in mice [39]. Similar to their data, we found that GC showed beneficial effect on DSS-induced colitis in mice, such as less body weight loss, improved survival rate, weaker pathological damage, and decreased production of proinflammatory cytokines compared to the control group exposed to DSS, and GC treatment also attenuated cytokines production and suppressed NF-\(\kappa\)B activation in RAW264.7 cells after LPS stimulation.

In recent years, tens of thousands of long noncoding RNAs (lncRNAs) have been identified in the mammalian genomes, many of which have been implicated in TLRs/NF-\(\kappa\)B pathways. IncRNA Lethe was found to interact with NF-\(\kappa\)B subunit RelA to inhibit RelA DNA binding and target gene activation; furthermore, Lethe level decreases with organismal age, a physiological state associated with increased NF-\(\kappa\)B activity [19]. TLR signaling could induce IncRNA-Cox2, which serves as both repressor and activator of genes through interactions with various regulatory complexes [40].
A natural antisense transcript, AS-IL1α, was found to control inducible transcription of the proinflammatory cytokine IL-1α upon TLRs stimulations [41]. Liu et al. report that NKILA is an essential IncRNA that regulates NF-κB signaling and represses inflammation; NKILA can bind to NF-κB/IκB complex and inhibits NF-κB signaling by blocking the phosphorylation sites of IκB and stabilizing the complex [42]. Li et al. identified IncRNA THRIL was essential for induction of TNFα expression through its interaction with hnRNPL during innate activation of THP-1 macrophages [43]. Cui et al. identified IncRNA-IL7R which inhibited LPS-induced proinflammatory response through regulating trimethylation of histone H3 at K27 at the proximal promoters of inflammatory mediators [44]. We then examined the effect of GC on the expression of these IncRNAs in DSS-treated mice and LPS stimulated macrophages. Interestingly, we found that, in mouse macrophage cell line RAW264.7, IncRNA Lethe was decreased after DSS challenge or LPS stimulation in control group, while GC treatment significantly increased Lethe expression in these conditions. The expressions of
Figure 5: GC suppressed NF-κB activation after LPS stimulation in RAW264.7 cells. (a) Luciferase reporter assay; (b) Western blot analysis; (c) quantification of protein level. RAW264.7 cells were transfected with NF-κB luciferase reporter plasmid together with pRL-TK-Renilla-luciferase plasmid (internal control); 24 hours later the cells were stimulated with LPS (100 ng/mL) together with GC (1 mg/mL) for 4 hours; the luciferase reporter assay was performed to examine the activation of NF-κB promoter (a); ** $p < 0.01$ versus control + DSS group; # $p < 0.05$ versus PBS + control group. The expressions of p-p65, p65, p-IKKβ, IKKβ, p-IxBα, and IxBα were examined by WB in RAW264.7 cells after stimulation with LPS and treatment with different quality of GC (b). Quantification of protein level of p-p65, p-IKKβ, p-IxBα in (b) and (c); * $p < 0.05$ versus control + LPS group, ** $p < 0.01$ versus control + LPS group, *** $p < 0.001$ versus control + LPS group, and # $p < 0.05$ versus untreated control group. The data are representative of three independent experiments (mean ± SD in (a, c)).

In conclusion, our current study provided the evidence that Guchang capsule could ameliorate DSS-induced colitis and illustrated its potential mechanism by inhibiting NF-κB pathway, which resulted in ameliorate effect on ulcerative colitis.

5. Conclusions

In conclusion, our current study provided the evidence that Guchang capsule could ameliorate DSS-induced colitis and illustrated its potential mechanism by inhibiting NF-κB pathway, which resulted in ameliorate effect on ulcerative colitis.
Figure 6: GC regulated NF-κB related lncRNAs expression. (a) QPCR analysis of lncRNA Lethe, lncRNA-Cox2, and lncRNA AS-IL1α expression in RAW264.7 cells after LPS (100 ng/mL) and GC (1 mg/mL) treatment for 4 hours; (b) qPCR analysis of lncRNA Lethe, lncRNA-Cox2, and lncRNA AS-IL1α mRNA level in mice after DSS (4%) and GC (2 g/kg) treatment for 6 days; (c) qPCR analysis of expression of lncRNA NKILA, lncRNA THRIL, and lncRNA-IL7R in THP-1-derived macrophages after LPS (100 ng/mL) and GC (1 mg/mL) treatment for 4 hours. The data are representative of three independent experiments (n = 5 per group in (b), mean ± SD). *P < 0.05; **P < 0.01; ***P < 0.001 versus control + LPS (DSS) group.
activation through regulating expression of NF-κB related lncRNAs. This study enriched the function of Guchang capsule in the treatment of ulcerative colitis and expanded our understanding of the mechanism of traditional Chinese medicine.

Competing Interests
The authors declare that there are no competing interests.

Authors’ Contributions
The authors thank Dr. Xuetao Cao for providing NF-κB activation through regulating expression of NF-κB related lncRNAs. This study enriched the function of Guchang capsule in the treatment of ulcerative colitis and expanded our understanding of the mechanism of traditional Chinese medicine.

Evidence-Based Complementary and Alternative Medicine

Acknowledgments
The authors thank Dr. Xuetao Cao for providing NF-κB luciferase reporter plasmid and pRL-TK-Renilla-luciferase plasmid.

References

[1] D. K. Podolsky, "Inflammatory bowel disease," New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002.

[2] D. C. Baumgart and S. R. Carding, "Inflammatory bowel disease: cause and immunobiology," Lancet, vol. 369, no. 9573, pp. 1627–1640, 2007.

[3] I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, "A novel method in the induction of experimental acute and chronic ulcerative colitis in mice," Gastroenterology, vol. 98, no. 3, pp. 694–702, 1990.

[4] I. Ordás, L. Eckmann, M. Talamini, D. C. Baumgart, and W. J. Sandborn, "Ulcerative colitis," The Lancet, vol. 380, no. 9853, pp. 1606–1619, 2012.

[5] M. Karin and A. Lin, "NF-κB at the crossroads of life and death," Nature Immunology, vol. 3, no. 3, pp. 221–227, 2002.

[6] S. S. Makarov, "NF-κB as a therapeutic target in chronic inflammation: recent advances," Molecular Medicine Today, vol. 6, no. II, pp. 441–448, 2000.

[7] M. S. Hayden and S. Ghosh, "Signaling to NF-κB," Genes and Development, vol. 18, no. 18, pp. 2195–2224, 2004.

[8] G. Rogler, K. Brand, D. Vogl et al., "Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa," Gastroenterology, vol. 115, no. 2, pp. 357–369, 1998.

[9] S. Schreiber, S. Nikolaus, and J. Hampe, "Activation of nuclear factor κB inflammatory bowel disease," Gut, vol. 42, no. 4, pp. 477–484, 1998.

[10] F. Rafii, J. G. H. Ruseler-Van Embden, and L. M. C. van Lieshout, "Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments," Digestive Diseases and Sciences, vol. 44, no. 3, pp. 637–642, 1999.

[11] F. Peris-Bondia, A. Latorre, A. Artacho, A. Moya, and G. D’Auria, "The active human gut microbiota differs from the total microbiota," PLoS ONE, vol. 6, no. 7, Article ID e22448, 2011.

[12] M. Rojas, C. R. Woods, A. L. Mora, J. Xu, and K. L. Brigham, "Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 288, no. 2, pp. L333–L341, 2005.

[13] Y. Imai, K. Kuba, G. G. Neely et al., "Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury," Cell, vol. 133, no. 2, pp. 235–249, 2008.

[14] H.-Z. Yang, J.-P. Wang, S. Mi et al., "TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury," The American Journal of Pathology, vol. 180, no. 1, pp. 275–292, 2012.

[15] G. Bonizzi and M. Karin, "The two NF-κB activation pathways and their role in innate and adaptive immunity," Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004.

[16] M. T. Ganter, J. Roux, B. Miyazawa et al., "Interleukin-ibeta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms," Circulation Research, vol. 102, no. 7, pp. 804–812, 2008.

[17] S. Katayama, Y. Tomaru, T. Kasukawa et al., "Antisense transcribed in the mammalian transcriptome," Science, vol. 309, no. 5740, pp. 1564–1566, 2005.

[18] T. Derrien, R. Johnson, G. Bussotti et al., "The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression," Genome Research, vol. 22, no. 9, pp. 1775–1789, 2012.

[19] N. A. Rapicavoli, K. Qu, J. Zhang, M. Mikhail, R.-M. Laberge, and H. Y. Chang, "A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics," eLife, vol. 2, Article ID e00762, 2013.

[20] D. A. Drossman, "The functional gastrointestinal disorders and the rome III process," Gastroenterology, vol. 130, no. 5, pp. 1377–1390, 2006.

[21] S. J. Halpin and A. C. Ford, "Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis," American Journal of Gastroenterology, vol. 107, no. 10, pp. 1474–1482, 2012.

[22] J. Keohane, C. O'Mahony, L. O'Mahony, E. M. Quigley, and F. Shanahan, "Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?" The American Journal of Gastroenterology, vol. 105, no. 8, pp. 1788–1795, 2010.

[23] J.-L. Tang, B.-Y. Liu, and K.-W. Ma, "Traditional Chinese medicine," The Lancet, vol. 372, no. 9654, pp. 1938–1940, 2008.

[24] D. Normile, "The new face of traditional Chinese medicine," Science, vol. 299, no. 5604, pp. 188–190, 2003.

[25] H. An, H. Xu, M. Zhang et al., "Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism," Blood, vol. 105, no. 12, pp. 4685–4692, 2005.

[26] J. T. Y. Kung, D. Colognori, and J. T. Lee, "Long noncoding RNAs: past, present, and future," Genetics, vol. 193, no. 3, pp. 651–669, 2013.

[27] M. Cabili, C. Trapnell, L. Goff et al., "Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses," Genes and Development, vol. 25, no. 18, pp. 1915–1927, 2011.

[28] J. L. Rinn and H. Y. Chang, "Genome regulation by long noncoding RNAs," Annual Review of Biochemistry, vol. 81, pp. 145–166, 2012.

[29] K. A. Fitzgerald and D. R. Caffrey, "Long noncoding RNAs in innate and adaptive immunity," Current Opinion in Immunology, vol. 26, no. 1, pp. 140–146, 2014.
[30] M. Noti, N. Corazza, C. Mueller, B. Berger, and T. Brunner, “TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis,” *Journal of Experimental Medicine*, vol. 207, no. 5, pp. 1057–1066, 2010.

[31] O. H. Nielsen, J. T. Bjerrum, H. Herfarth, and G. Rogler, “Recent advances using immunomodulators for inflammatory bowel disease,” *Journal of Clinical Pharmacology*, vol. 53, no. 6, pp. 575–588, 2013.

[32] S. Danese, “New therapies for inflammatory bowel disease: from the bench to the bedside,” *Gut*, vol. 61, no. 6, pp. 918–932, 2012.

[33] J. Meier and A. Sturm, “Current treatment of ulcerative colitis,” *World Journal of Gastroenterology*, vol. 17, no. 27, pp. 3204–3212, 2011.

[34] H. Y. Won, E. J. Jang, K. Lee et al., “Ablation of peroxiredoxin II attenuates experimental colitis by increasing FoxO1-induced Foxp3+ regulatory T cells,” *The Journal of Immunology*, vol. 191, no. 8, pp. 4029–4037, 2013.

[35] L. Andresen, V. L. Jørgensen, A. Perner, A. Hansen, J. Eugen-Olsen, and J. Rask-Madsen, “Activation of nuclear factor κB in colonic mucosa from patients with collagenous and ulcerative colitis,” *Gut*, vol. 54, no. 4, pp. 503–509, 2005.

[36] S. Schreiber, “The complicated path to true causes of disease: role of nuclear factor κB in inflammatory bowel disease,” *Gut*, vol. 54, no. 4, pp. 444–445, 2005.

[37] Y.-A. Song, Y.-L. Park, K.-Y. Kim et al., “Black tea extract prevents lipopolysaccharide-induced NF-κB signaling and attenuates dextran sulfate sodium-induced experimental colitis,” *BMC Complementary and Alternative Medicine*, vol. 11, article 91, 2011.

[38] X. Li, Y. Xu, C. Zhang et al., “Protective effect of calculus bovis sativus on dextran sulphate sodium-induced ulcerative colitis in mice,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 469506, 8 pages, 2015.

[39] R. K. Dave, M. E. Dinger, M. Andrew, M. Askarian-Amiri, D. A. Hume, and S. Kellie, “Regulated expression of PTPRI/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli,” *PLoS ONE*, vol. 8, no. 6, Article ID e68306, 2013.

[40] N. E. Iiott, J. A. Heward, B. Roux et al., “Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes,” *Nature Communications*, vol. 5, article 3979, 2014.

[41] J. Chan, M. Atianand, Z. Jiang et al., “Cutting edge: a natural antisense transcript, AS-IL1α, controls inducible transcription of the proinflammatory cytokine IL-1α,” *The Journal of Immunology*, vol. 195, no. 4, pp. 1359–1363, 2015.

[42] B. Liu, L. Sun, Q. Liu et al., “A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis,” *Cancer Cell*, vol. 27, no. 3, pp. 370–381, 2015.

[43] Z. Li, T.-C. Chiao, K.-Y. Chang et al., “The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 3, pp. 1002–1007, 2014.

[44] H. Cui, N. Xie, Z. Tan et al., “The human long noncoding RNA Inc-IL7R regulates the inflammatory response,” *European Journal of Immunology*, vol. 44, no. 7, pp. 2085–2095, 2014.